Digital Biomarkers Market

Digital Biomarkers Market by Content, Purpose, Type of Biomarker, Therapeutic Area, Business Model and by Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    253

  • Pages
    272

  • View Count
    15434

Digital Biomarkers Market Overview

The digital biomarkers market is estimated to be worth $1.45 billion in 2021 and is expected to grow at compounded annual growth rate (CAGR) of 36% during the forecast period.

Video Thumbnail

From periodically monitoring disease progression in patients to developing customized therapies based on genetic predisposition, biomarkers (which are specific indicators of biological events) have become an indispensable aspect of contemporary healthcare solutions / practices. Ongoing digitization efforts in the healthcare industry have led to the development of a number of digital solutions, which are capable of generating, collecting, and tracking medical data. From this data, details of anatomical, physiological, and molecular events, and even behavior-related patterns in humans, or digital biomarkers, have been acknowledged as viable inputs to explain, influence and / or predict health-related outcomes. Digital biomarkers are analyzed in silico, using advanced analytical algorithms and artificial intelligence (AI) enabled tools, and therefore, can be used to rapidly generate actionable insights and identify previously undetected biological events (obscured by the shortcomings of manual processes). In this context, regulatory bodies across the world have actually begun evaluating software as a medical device. Fundamentally, digital biomarkers are identified / measured using sensors and algorithms across the plethora of available connected medical devices and other health-focused software solutions. Moreover, the fact that the procurement / analysis of digital biomarkers are not limited to the physical confines of the clinical environment, presents new opportunities to revolutionize disease diagnosis, patient monitoring and clinical trial conduct. When combined with specific phenotypic signatures, digital biomarkers have demonstrated the potential to be used to generate insights related to esoteric medical fields, such as psychiatry and neurology. In fact, experts believe that future diagnostic / treatment protocols for certain mental health indications are likely to be underpinned by digital biomarkers, similar to how the management of diabetes and hypertension are underpinned by biochemical biomarkers.

 

Context of Digital Biomarkers Market List of Digital Solutions for Biomarkers in Digital Biomarkers Market Current Market Trends in Digital Biomarkers Market

In the current pandemic scenario, medical professionals are trying to identify digital biomarkers that can facilitate the successful screening / diagnosis of COVID-19 patients, remotely. For instance, the National Institutes of Health (NIH) has tasked physIQ with developing and validating an algorithm, which can use existing wearable biosensor-derived analytics (generated by the company’s pinpointIQ™ cloud platform) to discover a novel digital biomarker for COVID-19 associated decompensation. In this regard, it is worth noting that the development of tools to capture digital biomarkers and analyze them, requires multidisciplinary (including computer science and engineering, as well as neology and medicine) expertise. Currently, several successful start-ups claim to be involved in designing and developing the necessary software / hardware solutions for the abovementioned purposes. Most of these companies have also received significant capital investments to support their respective product development initiatives. One of the primary challenges encountered by innovators in this market is related to regulatory review. Digital biomarkers are subjected to the same level of regulatory scrutiny as their traditional counterparts. Moreover, there is an evident need for a systematic approach to assess the quality and utility of digitized renderings of biological events, in order to gauge their safety and efficacy in informing health-related decision making. Despite existing challenges, this niche, but emerging domain, is expected to evolve complementary to digital therapeutics, with pioneers in the field poised to benefit from the first-to-market advantage. Given the recent rise in partnership activity in this field, and the growing demand for remote diagnostic and therapeutic solutions (mostly influenced by the pandemic), we believe that the digital biomarkers market is likely to witness a healthy market growth during the forecast period.

Product Competitiveness Analysis in Digital Biomarkers Market Future Market Trends in Digital Biomarkers Market Global Events Analysis in Digital Biomarkers Market

Key Companies in Digital Biomarkers Market

Examples of key companies engaged in digital biomarkers market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Acculi Labs, Canary Health Technologies, Empatica, IXICO, Kinsa, Progentec Diagnostics and Vocalis Health. This market report includes an easily searchable excel database of all the companies providing digital biomarkers solutions, worldwide.

Recent Developments in Digital Biomarkers Market:

Several recent developments have taken place in the field of digital biomarkers market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In September 2023, Polarean Imaging collaborated with VIDA Diagnostics in order to enable the Polarean xenon 129 MRI platform to accelerate clinical and research use. 
  • In May 2023, IMVARIA published data from a study evaluating lead non-invasive digital biomarker Fibresolve revealing its supplemental ability to predict mortality in patients with interstitial lung disease. 
  • In May 2023, Fujitsu in collaboration with Kyoto University and Chordia Therapeutics launched AI trials to discover biomarkers for new cancer drugs.

Scope of the Report

The “Digital Biomarkers Market by Content of Solution (Standalone Software Solutions and Combination Offerings), Purpose of Solution (Diagnosis, Early Screening, Monitoring, and Predictive Insights), Type of Biomarker (Cognitive, Idiosyncratic, Physiological, Vocal, and Other Biomarkers), Therapeutic Area (Autoimmune Disorders, Cardiovascular Disorders, Infectious Disorders, Mental Health Problems, Neurological Disorders, Respiratory Disorders, Substance Use Disorders, and Other Disorders), Business Model (B2B and B2C), and by Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2021-2030 ” market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities of the digital biomarkers market. The market research report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in digital biomarkers market.

Funding and Investment Analysis in Digital Biomarkers Market Partnerships and Collaborations Analysis in Digital Biomarkers Market Big Pharma Initiatives in Digital Biomarkers Market

Amongst other elements, the market research report includes:

  • An overview of the current market landscape of digital solutions for biomarkers, including information on current status (approved, marketed, USFDA submission, research and development, proof-of-concept, and discovery), content of solution (combination offering of  software application / gaming solution + AI support or device or personal coach, and standalone software / gaming solution ), purpose of solution (diagnosis, early screening, monitoring and predictive insights), type of biomarker (cognitive, idiosyncratic, molecular, neurophysiological, physiological, respiratory, vocal, and others ), target indication(s), therapeutic area(s), target population, and prescription requirement. In addition, it highlights the companies engaged in developing digital solutions for biomarkers, along with information on their year of establishment, company size, type of business model used (B2B and B2C) and location of headquarters.
  • An in depth analysis of the contemporary market trends, presented using five schematic representations, including [A] a bubble analysis comparing the leading players engaged in the development of digital solutions for biomarkers, based on various parameters (such as product portfolio strength, type of biomarker and company size), [B] a grid representation illustrating the distribution of digital solutions for biomarkers based on their current status, content of solution and target therapeutic area, [C] an insightful tree map representation of digital solutions for biomarkers based on their therapeutic area and company size, [D] a world map representation highlighting the regional distribution of developer companies, and [E] a comparative grid representation to highlight the current and likely future market landscape based on status of development, type of biomarker and therapeutic area.  
  • Elaborate profiles of prominent players that are either currently engaged in developing or have developed digital solutions for biomarkers. Each company profile features a brief overview of the company (with information on its year of establishment, number of employees, location of headquarters and key members of the executive team), details related to their respective product portfolios, recent developments and an informed future outlook.
  • A detailed product competitiveness analysis of digital solutions for biomarkers taking into consideration several relevant parameters, such as current status, content of solution, purpose of solution, therapeutic area, and prescription requirement.
  • An analysis of the recent global events (summits / forums / conferences / annual meetings) that were organized for stakeholders engaged in digital biomarkers market, highlighting the evolution of discussion topics related to digital solutions for biomarkers. The chapter also includes details on type of event, regional distribution, emerging agendas, popular organizers, and most active industry and non-industry players.
  • An elaborate analysis of the investments, including seed financing, venture capital financing, debt financing, grants / awards, made at various stages of development in companies that are engaged in this field, during the period 2012-2020 (till September). 
  • An analysis of the partnerships that have been inked by stakeholders in digital biomarkers market, in the period between 2014 and 2020 (till September), covering marketing and distribution agreements, mergers / acquisitions, pilot programs, product / technology integration agreements, product / technology licensing agreements, product development agreements, product development and commercialization agreements, product evaluation agreements, and research and development agreements.
  • An analysis of the various digital solutions for biomarkers focused initiatives carried out by big pharma players (out of top 25 established pharmaceutical players), featuring [A] an analysis highlighting information on clinical research activity, funding, partnership activity, research publications, and participation in conferences, and [B] a spider web representation of the individual competitiveness of the initiatives of big pharma players based on multiple relevant parameters.
  • An insightful discussion on how the recent COVID-19 pandemic is likely to impact the overall digital solutions for biomarkers market, along with information on the key initiatives undertaken by big pharma players to overcome the challenges faced due to the pandemic.

The key objective of digital biomarkers market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for digital biomarkers market during the forecast period. Based on multiple parameters, likely adoption trends, and expected price variations for these products, we have provided an informed estimate of the evolution of the market for the forecast period 2021-2030. The market report also features the likely distribution of the current and forecasted opportunity within digital solutions for biomarkers market across [A] content of solution (combination offering of software application + device or AI, and standalone software applications), [B] purpose of solution (diagnosis, early screening, monitoring and predictive insights), [C] type of biomarker (cognitive, idiosyncratic, physiological, vocal, and other biomarkers), [D] therapeutic area (autoimmune disorders, cardiovascular disorders, infectious disorders, mental health problems, neurological disorders, respiratory disorders, substance use disorders, and other disorders), [E] business model (B2B (healthcare providers, payers, employers and pharmaceutical companies) and B2C (patients and caregivers)), and [F] key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. The opinions and insights presented in the market report were influenced by discussions held with senior stakeholders in the industry. The market research report features detailed transcripts of interviews held with the following industry stakeholders: 

  • Edouard Gasser (Co-Founder and Chief Executive Officer, Tilak Healthcare)
  • Michael Seggev (Chief Commercial Officer, Vocalis Health)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What are digital biomarkers?

Answer: Digital biomarkers analyze biomarkers in silico using advanced analytical algorithms and AI enabled tools, and therefore, can be used to rapidly generate actionable insights and identify previously undetected biological events.

Question 2: How big is the digital biomarkers market?

Answer: The digital biomarkers market size is estimated to be worth $1.45 billion in 2021.

Question 3: What is the projected market growth of the digital biomarkers market?

Answer: The digital biomarkers market is expected to grow at compounded annual growth rate (CAGR) of 36% during the forecast period 2021 – 2030.

Question 4: Who are the leading players in the digital biomarkers market?

Answer: Examples of key companies engaged in digital biomarkers market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Acculi Labs, Canary Health Technologies, Empatica, IXICO, Kinsa, Progentec Diagnostics and Vocalis Health.

Question 5: How much money has been invested by stakeholders in the digital biomarkers market?

Answer: Over USD 900 million has been invested by stakeholders in the digital biomarkers market, highlighting the growing opportunities within the industry.

Question 6: What are the advantages in using digital biomarkers?

Answer: Digital biomarkers use sensors and algorithms across the plethora of available connected medical devices and other health-focused software solutions to identify potential biomarkers. Moreover, the fact that the procurement / analysis of digital biomarkers are not limited to the physical confines of the clinical environment, presents new opportunities to revolutionize disease diagnosis, patient monitoring and clinical trial conduct.

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com